Allianz Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Allianz Asset Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.29M	Buy	700,516 +250,728	+56%	+$2.09M	﹤0.01%	1235
2025 Q4	$3.74M	Buy	449,788 +257,628	+134%	+$2.77M	﹤0.01%	1269
2025 Q3	$2.8M	Buy	+192,160	New	+$2.3M	﹤0.01%	1364
2024 Q2	–	Sell	-34,712	Closed	-$1.61M	–	2148
2024 Q1	$1.61M	Buy	34,712 +6,884	+25%	+$356K	﹤0.01%	1260
2023 Q4	$1.88M	Hold	27,828	–	–	﹤0.01%	1354
2023 Q3	$2.01M	Hold	27,828	–	–	﹤0.01%	1433
2023 Q2	$2.07K	Buy	27,828 +5,000	+22%	+$296K	﹤0.01%	2019
2023 Q1	$1.21M	Buy	22,828 +5,922	+35%	+$375K	﹤0.01%	1611
2022 Q4	$1.14M	Hold	16,906	–	–	﹤0.01%	1463
2022 Q3	$2.11M	Buy	+16,906	New	+$2.01M	﹤0.01%	1215

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz Asset Management's DNA Position: Q1 2026 in Review

Allianz Asset Management increased its Ginkgo Bioworks (DNA) stake by 56% in Q1 2026, buying an estimated $2.09M and bringing the position to 700,516 shares worth $4.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Allianz Asset Management first reported a position in DNA in Q3 2022 and has held it in 10 quarters since. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Allianz Asset Management held 700,516 shares of Ginkgo Bioworks worth $4.29M as of Q1 2026.
Allianz Asset Management bought 250,728 Ginkgo Bioworks shares in Q1 2026, an estimated $2.09M.
Ginkgo Bioworks made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1235 holding.
Allianz Asset Management first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 10 quarters since.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.